Investigational ALS drug prolongs patient survival in clinical trial

(Massachusetts General Hospital) An experimental medication that was recently shown to slow the progression of amyotrophic lateral sclerosis has now demonstrated the potential to also prolong patient survival. The findings come from a clinical trial conducted by investigators at the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Amylyx Pharmaceuticals, Inc., the company that manufactures the medication.